Micro-and nanoplastics (MNPs) are ubiquitous in aquatic and terrestrial environments, and
detrimental biological effects have been observed on a variety of organisms, from bacteria …

Brain delivery is one of the major challenges in drug development because of the high
number of patients suffering from neural diseases and the low efficiency of the treatments …

Humans are exposed to micro-and-nano plastics (MNPs) through various routes, but the
adverse health effects of MNPs on different organ systems are not yet fully understood. This …

Although many agents have therapeutic potentials for central nervous system (CNS)
diseases, few of these agents have been clinically used because of the brain barriers. As the …

Effective therapy lies in achieving a therapeutic amount of drug to the proper site in the body
and then maintaining the desired drug concentration for a sufficient time interval to be …

Clinically efficacious medication in anticancer therapy has been successfully designed with
liposome-based nanomedicine. The liposomal formulation in cancer drug delivery can be …

The protective properties of the blood–brain barrier (BBB) are conferred by the intricate
architecture of its endothelium coupled with multiple specific transport systems expressed on …

During the research and development of new drugs directed at the central nervous system,
there is a considerable attrition rate caused by their hampered access to the brain by the …

1. INTRODUCTION In his 1959 keynote lecture “There is plenty of room at the bottom”,
Richard Feynman introduced the concepts that would later form the basis of a new era of …

The activation of the brain renin-angiotensin system (RAS) plays a pivotal role in the
pathophysiology of cognition. While the brain RAS has been studied before in the context of …